Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
KPTI's Cash to Debt is ranked higher than
87% of the 763 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.71 vs. KPTI: No Debt )
Ranked among companies with meaningful Cash to Debt only.
KPTI' s Cash to Debt Range Over the Past 10 Years
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.92
KPTI's Equity to Asset is ranked higher than
95% of the 701 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. KPTI: 0.92 )
Ranked among companies with meaningful Equity to Asset only.
KPTI' s Equity to Asset Range Over the Past 10 Years
Min: -21.26  Med: 0.92 Max: 0.98
Current: 0.92
-21.26
0.98
Interest Coverage No Debt
KPTI's Interest Coverage is ranked lower than
99.99% of the 461 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.94 vs. KPTI: No Debt )
Ranked among companies with meaningful Interest Coverage only.
KPTI' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: 7.56
M-Score: -2.04
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -47630.40
KPTI's Operating margin (%) is ranked lower than
100% of the 708 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.77 vs. KPTI: -47630.40 )
Ranked among companies with meaningful Operating margin (%) only.
KPTI' s Operating margin (%) Range Over the Past 10 Years
Min: -47630.4  Med: -8772.61 Max: -2506.31
Current: -47630.4
-47630.4
-2506.31
Net-margin (%) -47272.40
KPTI's Net-margin (%) is ranked lower than
100% of the 711 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.28 vs. KPTI: -47272.40 )
Ranked among companies with meaningful Net-margin (%) only.
KPTI' s Net-margin (%) Range Over the Past 10 Years
Min: -47272.4  Med: -8771.83 Max: -2505.99
Current: -47272.4
-47272.4
-2505.99
ROE (%) -51.45
KPTI's ROE (%) is ranked lower than
88% of the 741 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.97 vs. KPTI: -51.45 )
Ranked among companies with meaningful ROE (%) only.
KPTI' s ROE (%) Range Over the Past 10 Years
Min: -58.34  Med: -53.44 Max: -41.9
Current: -51.45
-58.34
-41.9
ROA (%) -48.12
KPTI's ROA (%) is ranked lower than
91% of the 765 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.77 vs. KPTI: -48.12 )
Ranked among companies with meaningful ROA (%) only.
KPTI' s ROA (%) Range Over the Past 10 Years
Min: -372.3  Med: -48.40 Max: -40.03
Current: -48.12
-372.3
-40.03
ROC (Joel Greenblatt) (%) -3627.49
KPTI's ROC (Joel Greenblatt) (%) is ranked lower than
95% of the 757 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.44 vs. KPTI: -3627.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
KPTI' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -11974.25  Med: -4956.58 Max: -3818.37
Current: -3627.49
-11974.25
-3818.37
» KPTI's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

KPTI Guru Trades in

Q2 2014

KPTI Guru Trades in Q2 2014

Paul Tudor Jones 15,000 sh (New)
Steven Cohen 8,000 sh (unchged)
» More
Q3 2014

KPTI Guru Trades in Q3 2014

Steven Cohen 39,400 sh (+392.50%)
Paul Tudor Jones Sold Out
» More
Q4 2014

KPTI Guru Trades in Q4 2014

Steven Cohen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with KPTI

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.43
KPTI's P/B is ranked higher than
71% of the 729 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.82 vs. KPTI: 1.43 )
Ranked among companies with meaningful P/B only.
KPTI' s P/B Range Over the Past 10 Years
Min: 1  Med: 4.15 Max: 10.63
Current: 1.43
1
10.63
P/S 1134.27
KPTI's P/S is ranked lower than
100% of the 691 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.76 vs. KPTI: 1134.27 )
Ranked among companies with meaningful P/S only.
KPTI' s P/S Range Over the Past 10 Years
Min: 103.74  Med: 2756.67 Max: 16895
Current: 1134.27
103.74
16895
EV-to-EBIT -0.93
KPTI's EV-to-EBIT is ranked lower than
99.99% of the 525 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.51 vs. KPTI: -0.93 )
Ranked among companies with meaningful EV-to-EBIT only.
KPTI' s EV-to-EBIT Range Over the Past 10 Years
Min: -26.3  Med: -7.70 Max: 1.6
Current: -0.93
-26.3
1.6
EV-to-EBITDA -0.93
KPTI's EV-to-EBITDA is ranked lower than
99.99% of the 552 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.66 vs. KPTI: -0.93 )
Ranked among companies with meaningful EV-to-EBITDA only.
KPTI' s EV-to-EBITDA Range Over the Past 10 Years
Min: -26.4  Med: -7.70 Max: 1.6
Current: -0.93
-26.4
1.6
Current Ratio 11.74
KPTI's Current Ratio is ranked higher than
93% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. KPTI: 11.74 )
Ranked among companies with meaningful Current Ratio only.
KPTI' s Current Ratio Range Over the Past 10 Years
Min: 0.49  Med: 11.74 Max: 47.98
Current: 11.74
0.49
47.98
Quick Ratio 11.74
KPTI's Quick Ratio is ranked higher than
93% of the 656 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. KPTI: 11.74 )
Ranked among companies with meaningful Quick Ratio only.
KPTI' s Quick Ratio Range Over the Past 10 Years
Min: 0.49  Med: 11.74 Max: 47.98
Current: 11.74
0.49
47.98

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.81
KPTI's Price/Net Cash is ranked higher than
88% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 11.97 vs. KPTI: 1.81 )
Ranked among companies with meaningful Price/Net Cash only.
KPTI' s Price/Net Cash Range Over the Past 10 Years
Min: 3  Med: 4.47 Max: 6.37
Current: 1.81
3
6.37
Price/Net Current Asset Value 1.79
KPTI's Price/Net Current Asset Value is ranked higher than
89% of the 428 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.81 vs. KPTI: 1.79 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
KPTI' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.96  Med: 4.41 Max: 6.3
Current: 1.79
2.96
6.3
Price/Tangible Book 1.45
KPTI's Price/Tangible Book is ranked higher than
76% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.50 vs. KPTI: 1.45 )
Ranked among companies with meaningful Price/Tangible Book only.
KPTI' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.4  Med: 4.40 Max: 5.92
Current: 1.45
2.4
5.92
Price/Median PS Value 0.41
KPTI's Price/Median PS Value is ranked higher than
91% of the 637 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.16 vs. KPTI: 0.41 )
Ranked among companies with meaningful Price/Median PS Value only.
KPTI' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.05  Med: 0.69 Max: 1.7
Current: 0.41
0.05
1.7
Earnings Yield (Greenblatt) (%) -108.74
KPTI's Earnings Yield (Greenblatt) (%) is ranked lower than
96% of the 740 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.20 vs. KPTI: -108.74 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
KPTI' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -106.65  Med: 145.45 Max: 344.4
Current: -108.74
-106.65
344.4

More Statistics

Revenue(Mil) $0
EPS $ -3.32
Short Percentage of Float23.83%
52-Week Range $4.83 - 30.82
Shares Outstanding(Mil)35.88

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil)
EPS($) -3.04 -2.18 -2.44
EPS without NRI($) -3.04 -2.18 -2.44
» More Articles for KPTI

Headlines

Articles On GuruFocus.com
Weekly CEO Sells Highlight: Karopharm Therapeuticcs Inc., Methode Electronics Inc., Gilead Sciences Jul 06 2014 

More From Other Websites
Why Earnings Season Could Be Great for Karyopharm Therapeutics (KPTI) May 06 2016
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016 May 02 2016
Karyopharm to Report First Quarter 2016 Financial Results on May 9, 2016 May 02 2016
Karyopharm Presents Data Demonstrating the Potential of Nuclear Export Protein Exportin 1 (XPO1)... Apr 20 2016
Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider Apr 06 2016
Karyopharm Taps TransPerfect as eTMF and Functional TMF Provider Apr 06 2016
Karyopharm to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
Karyopharm to Present at the 15th Annual Needham Healthcare Conference Apr 05 2016
How Karyopharm Therapeutics (KPTI) Stock Stands Out in a Strong Industry Apr 04 2016
Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus Mar 31 2016
Karyopharm Receives NIAID Grant to Advance Development of KPT-350 for the Treatment of Lupus Mar 31 2016
ETF’s with exposure to Karyopharm Therapeutics, Inc. : March 23, 2016 Mar 23 2016
Karyopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 21 2016
Karyopharm Therapeutics, Inc. :KPTI-US: Earnings Analysis: 2015 By the Numbers Mar 21 2016
KARYOPHARM THERAPEUTICS INC. Financials Mar 19 2016
Karyopharm to Present Data on Oncology Pipeline at the 2016 American Association for Cancer Research... Mar 16 2016
KARYOPHARM THERAPEUTICS INC. Files SEC form 10-K, Annual Report Mar 15 2016
Edited Transcript of KPTI earnings conference call or presentation 14-Mar-16 12:30pm GMT Mar 14 2016
Karyopharm Therapeutics posts 4Q loss Mar 14 2016
Karyopharm Therapeutics posts 4Q loss Mar 14 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK